Video

Part 2: Practical Considerations For Venetoclax in AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP, FHOPA

Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.

Related Videos
Related Content
Visualization of bispecific antibody attacking cell | Image Credit: © miss irine - stock.adobe.com
May 29th 2025

ASCO 2025: Adding Elranatamab to Daratumumab, Lenalidomide Induces Durable Responses in Newly Diagnosed Multiple Myeloma

Alexandra Gerlach, Associate Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Lymphoma cell | Image Credit: © Dr_Microbe - stock.adobe.com
May 29th 2025

Epcoritamab-bysp Yields Long-Term Disease Remission in Patients with Relapsed, Refractory Large B-Cell Lymphoma

Alexandra Gerlach, Associate Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Red blood cells | Image Credit: © Anusorn - stock.adobe.com
May 27th 2025

Phase 3 Trial Explores Imetelstat for Advanced Myelofibrosis After Promising Phase 2 Data

Alexandra Gerlach, Associate Editor
Man holding kettlebell handle | Image Credit: © WIrul - stock.adobe.com
May 23rd 2025

Physical Activity Can Improve Quality of Life in Patients With Newly Diagnosed Multiple Myeloma

Alexandra Gerlach, Associate Editor